Brokerage firm UBS Maintains its rating on Becton Dickinson and Co(NYSE:BDX). In a research note issued to the investors, the brokerage major Raises the price-target to $195.00 per share. The shares have been rated Buy. The rating by UBS was issued on Aug 5, 2016.
In a different note, On Jul 28, 2016, Jefferies said it Maintains its rating on Becton Dickinson and Co. In the research note, the firm Raises the price-target to $190.00 per share. The shares have been rated ‘Buy’ by the firm.
Becton Dickinson and Co (BDX) made into the market gainers list on Wednesdays trading session with the shares advancing 0.19% or 0.33 points. Due to strong positive momentum, the stock ended at $173.11, which is also near the day’s high of $173.3413. The stock began the session at $172.54 and the volume stood at 5,25,170 shares. The 52-week high of the shares is $177.775 and the 52 week low is $128.87. The company has a current market capitalization of $36,860 M and it has 21,29,25,840 shares in outstanding.
Becton Dickinson and Co has also declared a cash dividend of $0.6600 on Jul 26, 2016. The shares will quote ex-dividend on Sep 7, 2016 and the record date has been fixed on Sep 9, 2016. The dividend payable date has been fixed on Sep 30, 2016.
Becton Dickinson and Co(BDX) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $3.20B. Analysts had an estimated revenue of $3.22B. Earnings per share were $2.35. Analysts had estimated an EPS of $2.21.
Several Insider Transactions has been reported to the SEC. On Jun 14, 2016, John E Gallagher (VP, Corp Finance and Treasurer) sold 1,931 shares at $169.87 per share price.Also, On Jun 8, 2016, Nabil Shabshab (Executive Vice President) sold 5,080 shares at $168.75 per share price.On May 18, 2016, Jeffrey S Sherman (Sr. VP and General Counsel) sold 34,373 shares at $166.27 per share price, according to the Form-4 filing with the securities and exchange commission.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.